UNSPSC 51183101: Alrestatin

This classification denotes an aldose reductase inhibitor with the molecular formula C14H9NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 515DHK15LG, chemically known as 2,3-dihydro-1,3-dioxo-1h-benz(de)isochiolin-2-essigsaeure but more generally known as alrestatin, which bears US NIH Compound Identifier 2120. Alrestatin most often comes in natrium and sodium forms. European Medicines Agency schedules Alrestatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05373MIG.

UNSPSC 51183101 Alrestatin, a Commodity code, encompasses generic pharmaceutical products supplied through state and local cooperative purchasing agreements. State and local governments buy generic multi-source pharmaceuticals and over-the-counter products under this code through centralized procurement vehicles that negotiate pricing and supply terms with manufacturers and wholesalers; the work involves establishing framework agreements that make products available across participating jurisdictions at negotiated rates, with manufacturers responsible for regulatory compliance, product documentation, and supply-chain coordination through authorized distribution channels.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities including Oregon. Vendors must supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and submit detailed product specifications including NDC codes, SKUs, UPCs, generic descriptions, strength, dosage form, and manufacturing locations. Award evaluations weight price competitiveness at 75 percent, with the remaining 25 percent allocated to fixed pricing terms, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. Products must be available by May 15, 2026, with contract terms of two years for new vendors and optional extensions at MMCAP's discretion, while incumbents' agreements extend through June 30, 2028. Vendors must maintain $5 million commercial general liability insurance, comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act, hold contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place, and accept performance penalties of $200 to $1,500 per violation for reporting delays or supply failures.